No Risk of Myocardial Infarction Associated With Initial Antiretroviral Treatment Containing Abacavir: Short and Long-Term Results from ACTG A5001/ALLRT | Zendy

Heather J. Ribaudo | Zendy; Constance A. Benson | Zendy; Yu Zheng | Zendy; Susan L. Koletar | Zendy; Ann C. Collier | Zendy; Judith J. Lok | Zendy; Marlene Smurzynski | Zendy; Ronald J. Bosch | Zendy; B. Bastow | Zendy; Jeff Schouten | Zendy

Open Access

No Risk of Myocardial Infarction Associated With Initial Antiretroviral Treatment Containing Abacavir: Short and Long-Term Results from ACTG A5001/ALLRT

Author(s) -

Heather J. Ribaudo,

Constance A. Benson,

Yu Zheng,

Susan L. Koletar,

Ann C. Collier,

Judith J. Lok,

Marlene Smurzynski,

Ronald J. Bosch,

B. Bastow,

Jeff Schouten

Publication year - 2011

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciq244

Subject(s) - abacavir , medicine , hazard ratio , confounding , myocardial infarction , proportional hazards model , population , confidence interval , regimen , human immunodeficiency virus (hiv) , viral load , immunology , antiretroviral therapy , environmental health

Observational and retrospective clinical trial cohorts have reported conflicting results for the association of abacavir use with risk of myocardial infarction (MI), possibly related to issues that may bias estimation of treatment effects, such as time-varying confounders, informative dropout, and cohort loss due to competing events.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research